Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature

Grillo, Thaís Gagno; Ferreira, Daniele Nunes; Quaglio, Ana Elisa Valencise; Dutra, Renata de Medeiros; Baima, Júlio Pinheiro; Bazan, Silméia Garcia Zanati; Sassaki, Lígia Yukie

doi:10.4330/wjc.v15.i5.217

Cited by 5 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of TNF-α are concentration dependent and involve two pathways. In lower concentrations, survivor activating factor enhancement pathway is activated, while higher concentration leads to stimulation of death-promoting pathway functions[ 156 , 157 ]. Chung et al [ 158 ] evaluated the effect of infliximab in patients with New York heart association (NYHA) Class III or IV heart failure with ejection fraction ≤ 35% and found that patients in the 10 mg/kg infliximab group were more likely to die or be hospitalized for heart failure than patients in the placebo group or 5 mg/kg infliximab group (HR = 2.84, 95%CI: 1.01-7.97; P = 0.043).…”

Section: Heart Failurementioning

confidence: 99%

“…Routine screening tests for cardiovascular diseases prior to the administration of biologics is not recommended. However, employment of an echocardiogram prior to initiation of anti TNF therapy to evaluate baseline cardiac function is vital[ 105 , 157 ]. Although there are no specific guidelines for the use of anti TNF in heart failure, it is suggested to avoid anti TNF agents in patients with NYHA class III or IV disease and switching to an alternative non-TNF inhibitor in patients with patients who develop acute heart failure on anti TNFs[ 105 , 157 , 159 , 160 ].…”

Section: Heart Failurementioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular implications of inflammatory bowel disease: An updated review

Bhardwaj,

Singh,

Midha

et al. 2023

World J Cardiol

View full text Add to dashboard Cite

Emerging data highlights the heightened risk of atherosclerotic cardiovascular diseases (ASCVD) in patients with chronic inflammatory disorders, particularly those afflicted with inflammatory bowel disease (IBD). This review delves into the epidemiological connections between IBD and ASCVD, elucidating potential underlying mechanisms. Furthermore, it discusses the impact of current IBD treatments on cardiovascular risk. Additionally, the cardiovascular adverse effects of novel small molecule drugs used in moderate-to-severe IBD are investigated, drawing parallels with observations in patients with rheumatoid arthritis. This article aims to comprehensively evaluate the existing evidence supporting these associations. To achieve this, we conducted a meticulous search of PubMed, spanning from inception to August 2023, using a carefully selected set of keywords. The search encompassed topics related to IBD, such as Crohn’s disease and ulcerative colitis, as well as ASCVD, including coronary artery disease, cardiovascular disease, atrial fibrillation, heart failure, conduction abnormalities, heart blocks, and premature coronary artery disease. This review encompasses various types of literature, including retrospective and prospective cohort studies, clinical trials, meta-analyses, and relevant guidelines, with the objective of providing a comprehensive overview of this critical intersection of inflammatory bowel disease and cardiovascular health.

show abstract

Section: Heart Failurementioning

confidence: 99%